首页> 美国卫生研究院文献>Heart International >Arrhythmic death and ICD implantation after myocardial infarction
【2h】

Arrhythmic death and ICD implantation after myocardial infarction

机译:心肌梗死后心律失常性死亡和ICD植入

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Arrhythmic death remains one of the most important causes of mortality after an acute myocardial infarction also in the revascularization era. As a consequence, identification of patients at risk should be performed before discharge. Unfortunately, in the clinical practice, this evaluation is mainly based on detection of a depressed left ventricular ejection. This approach, however, cannot adequately distinguish arrhythmic versus non-arrhythmic risk.This issue is of critical relevance when considering that arrhythmic death can be significantly reduced by appropriate interventions of implantable cardioverter defibrillator. Available evidence, however, indicates that in the first month after myocardial infarction, device implantation does not significantly reduce cardiac mortality: it seems that the reduction of arrhythmic death is counterbalanced by an increase in rate of death from non arrhythmic cause. It is therefore to be hoped that, in the future, arrhythmic risk evaluation will be based not only on the extent of left ventricular dysfunction but also on the analysis of other risk markers such as those reflecting autonomic dysfunction, cardiac electrical instability and presence of subclinical inflammation.
机译:心律失常性死亡仍然是在血运重建时代急性心肌梗塞后死亡的最重要原因之一。因此,应在出院前对有风险的患者进行识别。不幸的是,在临床实践中,该评估主要基于对左心室射血抑制的检测。然而,这种方法不能充分地区分心律失常和非心律失常的风险。当考虑到通过植入式心脏复律除颤器的适当干预可以显着降低心律失常死亡时,该问题具有至关重要的意义。但是,现有证据表明,在心肌梗塞后的第一个月内,植入设备并不能显着降低心脏死亡率:似乎由于非心律失常引起的死亡率增加,可以抵消心律失常死亡的减少。因此,希望将来,心律失常风险评估将不仅基于左心室功能障碍的程度,而且还将基于其他风险标志物的分析,例如反映自主神经功能障碍,心脏电不稳定和亚临床症状的那些标志物炎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号